The Animal Medical Center, New York, New York, USA.
Veterinary Surgical Centers, Vienna, Virginia, USA.
J Vet Intern Med. 2021 May;35(3):1487-1495. doi: 10.1111/jvim.16109. Epub 2021 May 6.
Effective treatment options for nonresectable hepatic carcinoma (HC) in dogs are limited.
HYPOTHESIS/OBJECTIVE: Objectives were to report outcomes, complications, and tumor responses via computed tomography (CT) assessment after drug-eluting bead transarterial chemoembolization (DEB-TACE) for nonresectable HC in dogs. The authors hypothesized that major complications would be uncommon and short-term CT assessment would demonstrate stable disease or partial response.
Client-owned dogs (n = 16) with nonresectable HC.
Prospective, single-arm clinical trial. Drug-eluting bead transarterial chemoembolization was performed to varying levels of blood flow stasis. Computed tomography imaging was compared before and approximately 12 weeks after initial treatment.
Drug-eluting bead transarterial chemoembolization was successfully administered in all attempts. Based on percent change in elliptical tumor volume response (mL), stable disease (8/13; 62%) was the most common outcome followed by partial response (3/13; 23%) and progressive disease (2/13; 15%) with a median of 74 days (range, 39-125) after initial treatment. Median tumor volume (mL) after DEB-TACE decreased in volume by 13% (range, 56% decrease to 77% increase). Mild complications consistent with postembolization syndrome occurred after 7/27 (26%) treatments. Major complications occurred after 3/27 (11%) treatments: hepatic abscess/septicemia (2) and cholecystitis/death (1), resulting in treatment-induced death after 2/27 (7%) treatments. Median survival time after treatment was 337 days (range, 22-1061). Dogs with a presenting complaint of weight loss (P = .02) had a significantly shorter median survival time (126 days; range, 46-337) than those dogs without prior history of weight loss (582 days; range, 22-1061).
Drug-eluting bead transarterial chemoembolization for nonresectable HC is a feasible procedure, which promoted stable disease or partial response in 85% of dogs in this study sample.
目前，犬非手术治疗性肝癌（HC）的有效治疗方法十分有限。
假设/目的：本研究旨在报告采用载药微球动脉化疗栓塞术（DEB-TACE）治疗犬非手术治疗性 HC 的结果、并发症和通过 CT 评估肿瘤反应，并假设主要并发症不常见，且短期 CT 评估将显示疾病稳定或部分缓解。
16 只患有非手术治疗性 HC 的患犬。
前瞻性、单臂临床试验。根据血流淤滞程度，对患犬进行不同程度的 DEB-TACE。比较初始治疗前后的 CT 图像。
所有尝试均成功进行了 DEB-TACE。根据椭圆形肿瘤体积反应（mL）的百分比变化，疾病稳定（8/13；62%）是最常见的结果，其次是部分缓解（3/13；23%）和疾病进展（2/13；15%），初始治疗后中位数为 74 天（范围 39-125 天）。DEB-TACE 后，肿瘤体积中位数（mL）体积减少了 13%（范围 56%减少至 77%增加）。27 次治疗中有 7 次（26%）出现与栓塞后综合征一致的轻度并发症。3 次（11%）治疗出现主要并发症：肝脓肿/败血症（2 次）和胆囊炎/死亡（1 次），导致 2 次（7%）治疗出现治疗相关死亡。治疗后中位生存时间为 337 天（范围 22-1061 天）。与无体重减轻病史的患犬相比，以体重减轻为首发症状的患犬（P=0.02）的中位生存时间明显更短（126 天；范围 46-337 天）。
DEB-TACE 治疗犬非手术治疗性 HC 是一种可行的方法，本研究样本中 85%的犬表现出疾病稳定或部分缓解。
